Carnegie Investment Counsel’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $308K | Hold |
3,530
| – | – | 0.01% | 468 |
|
|
2025
Q1 | $218K | Hold |
3,530
| – | – | 0.01% | 473 |
|
|
2024
Q4 | $275K | Buy |
3,530
+350
| +11% | +$27.2K | 0.01% | 406 |
|
|
2024
Q3 | $213K | Sell |
3,180
-2,068
| -39% | -$139K | 0.01% | 447 |
|
|
2024
Q2 | $595K | Sell |
5,248
-100
| -2% | -$11.3K | 0.02% | 319 |
|
|
2024
Q1 | $742K | Sell |
5,348
-62
| -1% | -$8.6K | 0.02% | 315 |
|
|
2023
Q4 | $671K | Buy |
5,410
+1
| +0% | +$124 | 0.02% | 325 |
|
|
2023
Q3 | $505K | Buy |
5,409
+60
| +1% | +$5.6K | 0.02% | 348 |
|
|
2023
Q2 | $687K | Buy |
5,349
+34
| +0.6% | +$4.37K | 0.03% | 314 |
|
|
2023
Q1 | $617K | Sell |
5,315
-2
| -0% | -$232 | 0.02% | 323 |
|
|
2022
Q4 | $602K | Buy |
5,317
+5
| +0.1% | +$566 | 0.03% | 328 |
|
|
2022
Q3 | $428K | Hold |
5,312
| – | – | 0.02% | 359 |
|
|
2022
Q2 | $396K | Buy |
5,312
+420
| +9% | +$31.3K | 0.02% | 366 |
|
|
2022
Q1 | $626K | Sell |
4,892
-356
| -7% | -$45.6K | 0.02% | 321 |
|
|
2021
Q4 | $704K | Buy |
5,248
+568
| +12% | +$76.2K | 0.02% | 319 |
|
|
2021
Q3 | $640K | Buy |
4,680
+948
| +25% | +$130K | 0.02% | 290 |
|
|
2021
Q2 | $398K | Hold |
3,732
| – | – | 0.02% | 348 |
|
|
2021
Q1 | $335K | Buy |
3,732
+140
| +4% | +$12.6K | 0.01% | 362 |
|
|
2020
Q4 | $332K | Sell |
3,592
-200
| -5% | -$18.5K | 0.01% | 344 |
|
|
2020
Q3 | $391K | Buy |
3,792
+1,352
| +55% | +$139K | 0.02% | 316 |
|
|
2020
Q2 | $247K | Buy |
+2,440
| New | +$247K | 0.01% | 368 |
|